Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) patients

Next Previous
Trial Profile

Registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) patients

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imeroprubart (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 06 Feb 2026 According to Prioivant Therapeutics media release, this trial is fully enrolled and topline data expected in the second half of calendar year 2026.
  • 06 Feb 2026 Status changed from planning to active, no longer recruiting, according to Prioivant Therapeutics media release.
  • 07 Aug 2025 According to an Immunovant media release, top-line results from the proof-of-concept trial of IMVT-1402 in CLE is expected in year 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top